Skip to main content
SpringerLink
Log in

Neue Zulassungen geben mehr Therapiefreiheit

Multiple Sklerose

  • In|Fo|Pharm
  • Published:
InFo Neurologie & Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Satellitensymposium „Zwei neue Optionen in der Therapie der Multiplen Sklerose — Teriflunomid und Alemtuzumab“. 86. DGN-Kongress 2013, Dresden, 19.9.2013; Veranstalter: Genzyme

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Friederike Klein (freie Medizinjournalistin)

Authors
  1. Friederike Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klein, F. Neue Zulassungen geben mehr Therapiefreiheit. InFo Neurologie 16, 60 (2014). https://doi.org/10.1007/s15005-014-0039-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-014-0039-8

Search

Navigation